Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | GRK3 | P35626 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312178 | 0.91 | AXL (0.41) | AXLMAPK8GRM4MAPK10CRHR1 | |
| Hydrochloric Acid SCHEMBL3501027 | 0.89 | AXL (0.41) | AXLMAPK8GRM4MAPK10CRHR1 | |
| SCHEMBL2661733 | 0.69 | SMN1; SMN2 (0.41) | AXLGRM4ABL1BCRCTNNB1 | |
| SCHEMBL14631560 | 0.67 | AXL (0.46) | AXLMAPK8GRM4MAPK10ABL1 | |
| SCHEMBL2660889 | 0.67 | GAA (0.56) | AXLMAPK8ABL1BCR | |
| SCHEMBL25475400 | 0.67 | AXL (0.46) | AXLMAPK8GRM4ABL1BCR | |
| SCHEMBL13122322 | 0.67 | AXL (0.46) | AXLMAPK8ABL1BCRP2RX7 | |
| SCHEMBL28067226 | 0.67 | AXL (0.46) | AXLMAPK8GRM4MAPK10ABL1 | |
| SCHEMBL2661213 | 0.66 | GRM4 (0.57) | AXLGRM4 | |
| SCHEMBL11697971 | 0.65 | GAA (0.45) | MAPK8MAPK10CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144793-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | APP, BACE1, APBA1 | AXL 2825/4885MAPK8 3236/4885GRM4 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.